Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined anti-VEGF and low-dose triamcinolone versus anti-VEGF alone for macular edema due to central retinal vein occlusion
IRCT20201120049450N7Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of triamcinolone acetonide in macular edema and central retinal vein occlusion (CRVO) (2 arms), sponsored by Shiraz University of Medical Sciences. Started Apr 2026; status: completed.
02
Drugs
triamcinolone acetonide
03
Conditions
macular edemacentral retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on IRCT20201120049450N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201120049450N7.